After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Day One Biopharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Day One Biopharmaceuticals Inc is $1.31B. A total of 0.86 million shares were traded on the day, compared to an average of 1.14M shares.
In the most recent transaction, Blackman Samuel C. sold 30,000 shares of DAWN for 13.31 per share on Dec 10 ’24. After the transaction, the HEAD OF R&D now owns 1,034,015 company shares. In a previous transaction on Nov 18 ’24, Bender Jeremy sold 10,554 shares at 13.21 per share. DAWN shares that CHIEF EXECUTIVE OFFICER owns now total 108,377.
Among the insiders who sold shares, Blackman Samuel C. disposed of 2,206 shares on Nov 18 ’24 at a per-share price of $13.21. This resulted in the HEAD OF R&D holding 1,064,015 shares of DAWN after the transaction. In another insider transaction, Dubow Adam sold 3,165 shares at $13.21 per share on Nov 18 ’24. Company shares held by the GENERAL COUNSEL now total 32,162.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, DAWN has a high of $18.07 and a low of $11.13.
As of this writing, DAWN has an earnings estimate of -$0.35 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.27 per share and a lower estimate of -$0.44.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. DAWN’s latest balance sheet shows that the firm has $284.31M in Cash & Short Term Investments as of fiscal 2021. There were $220.00k in debt and $8.66M in liabilities at the time. Its Book Value Per Share was $5.51, while its Total Shareholder’s Equity was $281.15M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DAWN is Buy with a score of 4.70.
